Skip to main navigation
Top Links - Left
BioNTech.com
Newsroom
Investors
Healthcare Professionals
English
Language switcher (Content)
English
German
Top Links - Right
Connect
Main Navigation
BioNTech.com
News
Events & Presentations
Financials
Financials
SEC Filings
Annual Reports
Quarterly Reports
Financial Calendar
Corporate Governance
Corporate Governance
Overview
Transparency
ESG
Stock Info
Stock Info
Stock Quote & Chart
Analyst Coverage
Shareholder Fraud Warning
Share Repurchase Program
Dividend Information
Investor FAQs
Annual General Meeting
Annual General Meeting
Annual General Meeting 2024
Annual General Meeting Archive
Contact Us
Newsroom
Investors
Healthcare Professionals
Breadcrumb
Investors
Search
Search
Filter by content type
(-)
News
(328)
Filter by content year
2024
(4)
2023
(30)
2022
(91)
2021
(125)
2020
(78)
Filter by form group
Filter by category
(-)
Other
(328)
All
(305)
Collaborators
(210)
Clinical
(67)
Financial
(48)
Events
(45)
Science
(42)
HR
(10)
Filter by category
Search
News
Pfizer und BioNTech geben erfolgreiche erste Zwischenanalyse ihres COVID-19-Impfstoffkandidaten in laufender Phase-3-Studie bekannt
News
Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study
News
BioNTech veröffentlicht Ergebnisse des dritten Quartals und Informationen zur Geschäftsentwicklung
News
BioNTech Announces Third Quarter 2020 Financial Results and Corporate Progress
News
Pfizer und BioNTech schließen Liefervereinbarung mit der EU über 200 Millionen Dosen ihres mRNA-basierten Impfstoffkandidaten BNT162b2 gegen COVID-19
News
Pfizer and BioNTech Reach an Agreement to Supply the EU with 200 Million Doses of Their BNT162b2 mRNA-based Vaccine Candidate against COVID-19
News
Pfizer und BioNTech reichen Antrag auf Notfallzulassung für COVID-19-Impfstoff bei der U.S. FDA ein
News
Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine
News
Pfizer und BioNTech veröffentlichen Ergebnisse der Phase-3-Studie mit COVID-19-Impfstoffkandidat BNT162b2 im The New England Journal of Medicine
News
Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine
Pagination
Page 1
Next page
››